Suppr超能文献

遗传药理学在 HIV 治疗中的双重作用:调控抗逆转录病毒药物耐药性和药物处置的突变和多态性。

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.

机构信息

McGill University AIDS Centre, Lady Davis Institute for Medical Research, 3755 Cote-Ste-Catherine Rd., Montréal, Québec, H3T 1E2, Canada.

出版信息

Pharmacol Rev. 2012 Jul;64(3):803-33. doi: 10.1124/pr.111.005553.

Abstract

Significant intra- and interindividual variability has been observed in response to use of pharmacological agents in treatment of HIV infection. Treatment of HIV infection is limited by high rates of adverse drug reactions and development of resistance in a significant proportion of patients as a result of suboptimal drug concentrations. The efficacy of antiretroviral therapy is challenged by the emergence of resistant HIV-1 mutants with reduced susceptibility to antiretroviral drugs. Moreover, pharmacotherapy of patients infected with HIV is challenging because a great number of comorbidities increase polypharmacy and the risk for drug-drug interactions. Drug-metabolizing enzymes and drug transporters regulate drug access to the systemic circulation, target cells, and sanctuary sites. These factors, which determine drug exposure, along with the emergence of mutations conferring resistance to HIV medications, could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. In this review, the major factors affecting the disposition of antiretroviral drugs, including key drug-metabolizing enzymes and membrane drug transporters, are outlined. Genetic polymorphisms affecting the activity and/or the expression of cytochromes P450 or UGT isozymes and membrane drug transport proteins are highlighted and include such examples as the association of neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine, and hyperbilirubinemia with indinavir and atazanavir. Mechanisms of drug resistance conferred by specific viral mutations are also reviewed, with particular attention to replicative viral fitness and transmitted HIV drug resistance with the objectives of providing a better understanding of mechanisms involved in HIV drug resistance and helping health care providers to better manage interpatient variability in drug efficacy and toxicity.

摘要

在治疗 HIV 感染时,使用药物治疗会出现显著的个体内和个体间的变异性。由于药物浓度不理想,很大一部分患者会出现不良反应和耐药性,从而限制了 HIV 感染的治疗。抗逆转录病毒治疗的疗效受到具有降低对抗逆转录病毒药物敏感性的耐药 HIV-1 突变体的出现的挑战。此外,由于许多合并症增加了多药治疗和药物相互作用的风险,HIV 感染者的药物治疗也具有挑战性。药物代谢酶和药物转运体调节药物进入全身循环、靶细胞和避难部位的能力。这些决定药物暴露的因素,以及导致 HIV 药物耐药的突变的出现,可以解释与抗逆转录病毒药物相关的疗效和不良反应的变异性。在这篇综述中,概述了影响抗逆转录病毒药物处置的主要因素,包括关键的药物代谢酶和膜药物转运体。强调了影响细胞色素 P450 或 UGT 同工酶和膜药物转运蛋白活性和/或表达的遗传多态性,包括与依非韦伦相关的神经毒性、与替诺福韦相关的肾毒性、与奈韦拉平相关的肝毒性以及与茚地那韦和阿扎那韦相关的高胆红素血症。还回顾了特定病毒突变赋予的耐药机制,特别关注复制病毒适应性和传播的 HIV 耐药性,目的是更好地了解 HIV 耐药性涉及的机制,并帮助医疗保健提供者更好地管理药物疗效和毒性的个体间变异性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验